Crossmark Global Holdings Inc. Grows Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Crossmark Global Holdings Inc. grew its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 284.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 210,484 shares of the company’s stock after buying an additional 155,795 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Takeda Pharmaceutical were worth $2,787,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of TAK. American Century Companies Inc. lifted its holdings in Takeda Pharmaceutical by 7.1% in the 2nd quarter. American Century Companies Inc. now owns 262,991 shares of the company’s stock worth $3,403,000 after buying an additional 17,363 shares during the period. Dimensional Fund Advisors LP lifted its stake in Takeda Pharmaceutical by 15.2% in the second quarter. Dimensional Fund Advisors LP now owns 114,254 shares of the company’s stock worth $1,478,000 after acquiring an additional 15,075 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Takeda Pharmaceutical by 38.6% in the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock valued at $43,000 after acquiring an additional 859 shares in the last quarter. AQR Capital Management LLC increased its position in Takeda Pharmaceutical by 153.7% during the 2nd quarter. AQR Capital Management LLC now owns 90,013 shares of the company’s stock valued at $1,165,000 after purchasing an additional 54,539 shares during the period. Finally, Millennium Management LLC raised its holdings in Takeda Pharmaceutical by 87.1% in the 2nd quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock worth $56,239,000 after purchasing an additional 2,023,707 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Down 1.5 %

Shares of TAK opened at $12.91 on Thursday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The firm’s 50-day moving average price is $13.35 and its 200-day moving average price is $13.90. The firm has a market capitalization of $41.06 billion, a price-to-earnings ratio of 22.25, a PEG ratio of 0.23 and a beta of 0.51.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.